Scholarlink

Background <p>The prognostic significance of miR-378 in cancers remains controversial. We carried out the meta-analysis to clarify the issue.</p> Methods <p>Related researches were obtained from PubMed, Web of Science and EMBASE. The search was conducted up until 10 September 2023. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to access the correlation between miR-378 and survival outcomes and clinicopathological features.</p> Results <p>16 articles were included in the meta-analysis. The pooled analysis showed that low miR-378 expression predicted poor overall survival (OS) (HR: 1.73, 95% CI: 1.09–2.74). No significant difference was discovered between low miR-378 expression and disease-free survival/ recurrence-free survival (DFS/RFS) (HR: 1.43; 95% CI: 0.79–2.59). Subgroup analysis revealed that the low miR-378 expression had better predictive value for CRC (HR: 2.97, 95% CI: 1.27–6.96), GC (HR: 2.12, 95% CI: 1.23–3.67) and glioma (HR: 3.87, 95% CI: 1.52–9.81). In addition, low miR-378 expression had positive correlation with lymph node metastasis (yes vs. no)(OR: 2.42, 95% CI: 1.55–2.87) and distant metastasis (yes vs. no) (OR: 1.26, 95% CI: 1.04–2.35).</p> Conclusion <p>MiR-378 could be an efficient prognostic biomarker in cancers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic significance of miR-378 in cancers: a meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月10日

查看全文
  • Lei Shi,
  • Jie Wei,
  • Yankun Shen,
  • Xiaoqiang Zhang,
  • Lixin Li,
  • Ying Deng

摘要

Background

The prognostic significance of miR-378 in cancers remains controversial. We carried out the meta-analysis to clarify the issue.

Methods

Related researches were obtained from PubMed, Web of Science and EMBASE. The search was conducted up until 10 September 2023. Hazard ratios (HRs) or odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to access the correlation between miR-378 and survival outcomes and clinicopathological features.

Results

16 articles were included in the meta-analysis. The pooled analysis showed that low miR-378 expression predicted poor overall survival (OS) (HR: 1.73, 95% CI: 1.09–2.74). No significant difference was discovered between low miR-378 expression and disease-free survival/ recurrence-free survival (DFS/RFS) (HR: 1.43; 95% CI: 0.79–2.59). Subgroup analysis revealed that the low miR-378 expression had better predictive value for CRC (HR: 2.97, 95% CI: 1.27–6.96), GC (HR: 2.12, 95% CI: 1.23–3.67) and glioma (HR: 3.87, 95% CI: 1.52–9.81). In addition, low miR-378 expression had positive correlation with lymph node metastasis (yes vs. no)(OR: 2.42, 95% CI: 1.55–2.87) and distant metastasis (yes vs. no) (OR: 1.26, 95% CI: 1.04–2.35).

Conclusion

MiR-378 could be an efficient prognostic biomarker in cancers.